Early-stage antisense products targeting Huntington's disease and amyotrophic lateral sclerosis are attracting the attention of big pharma companies, and are the first targets of a just announced broad collaboration between Japan's Takeda Pharmaceutical Co. Ltd. and the US's Wave Life Sciences Ltd.,designed to develop therapies for genetically defined neurological diseases.
The deal announced on Feb. 20 is multi-faceted and could see Cambridge, Mass.-based Wave Life Sciences receiving at least $230m...








